Clinton M. Carroll

Hematology | Oncology

330 23rd Ave N Ste 100
Nashville, TN 37203

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Incidence of Human Leukocyte Antigen (HLA) Class I Antibodies and Impact on Platelet Engraftment, Transfusions and Bleeding in Recipients of Gene Therapy for Sickle Cell Disease and Transfusion Dependent Beta Thalassemia.

Incidence of Human Leukocyte Antigen (HLA) Class I Antibodies and Impact on Platelet Engraftment, Transfusions and Bleeding in Recipients of Gene Therapy for Sickle Cell Disease and Transfusion Dependent Beta Thalassemia.

Journal: Transplantation and cellular therapy

Published: July 02, 2026

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.

Journal: The New England journal of medicine

Published: April 03, 2026

Safety and Feasibility of Fertility Preservation and Fertility Outcomes in Patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Undergoing Gene Therapy.

Safety and Feasibility of Fertility Preservation and Fertility Outcomes in Patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Undergoing Gene Therapy.

Journal: Transplantation and cellular therapy

Published: June 01, 2025

Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent β-Thalassemia.

Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent β-Thalassemia.

Journal: Transplantation and cellular therapy

Published: February 18, 2025

Sustained remission in a patient with PDGFR-beta-rearranged T-lymphoblastic lymphoma and complete remission with dasatinib.

Sustained remission in a patient with PDGFR-beta-rearranged T-lymphoblastic lymphoma and complete remission with dasatinib.

Journal: Pediatric blood & cancer

Published: June 18, 2019

Recurrent Acute Chest Syndrome in Pediatric Sickle Cell Disease: Clinical Features and Risk Factors.

Recurrent Acute Chest Syndrome in Pediatric Sickle Cell Disease: Clinical Features and Risk Factors.

Journal: Journal of pediatric hematology/oncology

Published: December 05, 2017

ETAA1 acts at stalled replication forks to maintain genome integrity.

ETAA1 acts at stalled replication forks to maintain genome integrity.

Journal: Nature cell biology

Published: April 11, 2016

A novel splice site mutation in SMARCAL1 results in aberrant exon definition in a child with Schimke immunoosseous dysplasia.

A novel splice site mutation in SMARCAL1 results in aberrant exon definition in a child with Schimke immunoosseous dysplasia.

Journal: American journal of medical genetics. Part A

Published: January 02, 2015

Unusual progression and subsequent improvement in cystic lung disease in a child with radiation-induced lung injury.

Unusual progression and subsequent improvement in cystic lung disease in a child with radiation-induced lung injury.

Journal: Pediatric radiology

Published: May 09, 2014

Phosphorylation of a C-terminal auto-inhibitory domain increases SMARCAL1 activity.

Phosphorylation of a C-terminal auto-inhibitory domain increases SMARCAL1 activity.

Journal: Nucleic acids research

Published: October 24, 2013

ATR phosphorylates SMARCAL1 to prevent replication fork collapse.

ATR phosphorylates SMARCAL1 to prevent replication fork collapse.

Journal: Genes & development

Published: July 23, 2013

Schimke Immunoosseous Dysplasia associated with undifferentiated carcinoma and a novel SMARCAL1 mutation in a child.

Schimke Immunoosseous Dysplasia associated with undifferentiated carcinoma and a novel SMARCAL1 mutation in a child.

Journal: Pediatric blood & cancer

Published: January 30, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026